Log in

Trimedyne Stock Price, Forecast & Analysis (OTCMKTS:TMED)

+0.81 (+21.60 %)
(As of 10/31/2019)
Today's Range
Now: $4.56
50-Day Range
MA: $3.93
52-Week Range
Now: $4.56
Volume100 shs
Average Volume84 shs
Market Capitalization$547,200.00
P/E RatioN/A
Dividend YieldN/A
Trimedyne, Inc manufactures and sells lasers, and disposable and reusable fiber-optic laser devices for use in the medical field. It offers lasers, fibers, needles, and switch tips for use in orthopedics, urology, ear and nose surgery, throat surgery, gynecology, gastrointestinal surgery, general surgery, and other medical specialties. The company also provides 80 watt and 30 watt holmium lasers, and side firing laser needles to treat herniated or ruptured spinal discs. Read More…

Industry, Sector and Symbol

Industry Electromedical equipment
SectorComputer and Technology
Current SymbolOTCMKTS:TMED



Sales & Book Value

Annual Sales$5.57 million



Market Cap$547,200.00
Next Earnings Date12/20/2019 (Estimated)
OptionableNot Optionable

Receive TMED News and Ratings via Email

Sign-up to receive the latest news and ratings for TMED and its competitors with MarketBeat's FREE daily newsletter.

Trimedyne (OTCMKTS:TMED) Frequently Asked Questions

What is Trimedyne's stock symbol?

Trimedyne trades on the OTCMKTS under the ticker symbol "TMED."

How were Trimedyne's earnings last quarter?

Trimedyne, Inc. (OTCMKTS:TMED) announced its quarterly earnings results on Tuesday, August, 27th. The technology company reported ($1.11) earnings per share for the quarter. The technology company earned $1.02 million during the quarter. View Trimedyne's Earnings History.

When is Trimedyne's next earnings date?

Trimedyne is scheduled to release their next quarterly earnings announcement on Friday, December 20th 2019. View Earnings Estimates for Trimedyne.

Has Trimedyne been receiving favorable news coverage?

News headlines about TMED stock have trended very negative this week, InfoTrie Sentiment reports. The research group ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Trimedyne earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave news coverage about the technology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for Trimedyne.

Who are some of Trimedyne's key competitors?

What other stocks do shareholders of Trimedyne own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Trimedyne investors own include Rank Group (RNK), Incyte (INCY), PDC Energy (PDCE), AFLAC (AFL), Diana Shipping (DSX), Cohen & Steers Clsd-End Optuny Fnd (FOF), National Fuel Gas (NFG), Safehold (SAFE), Snap (SNAP) and AnaptysBio (ANAB).

Who are Trimedyne's key executives?

Trimedyne's management team includes the folowing people:
  • Mr. Glenn D. Yeik, Interim Chairman, CEO & Pres (Age 51)
  • Mr. Brian T. Kenney, VP of Global Sales & Marketing (Age 62)

How do I buy shares of Trimedyne?

Shares of TMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Trimedyne's stock price today?

One share of TMED stock can currently be purchased for approximately $4.56.

How big of a company is Trimedyne?

Trimedyne has a market capitalization of $547,200.00 and generates $5.57 million in revenue each year. View Additional Information About Trimedyne.

What is Trimedyne's official website?

The official website for Trimedyne is http://www.trimedyne.com/.

How can I contact Trimedyne?

Trimedyne's mailing address is 5 HOLLAND BLDG #223, IRVINE CA, 92618. The technology company can be reached via phone at 949-951-3800.

MarketBeat Community Rating for Trimedyne (OTCMKTS TMED)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  47 (Vote Outperform)
Underperform Votes:  75 (Vote Underperform)
Total Votes:  122
MarketBeat's community ratings are surveys of what our community members think about Trimedyne and other stocks. Vote "Outperform" if you believe TMED will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TMED will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/13/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel